7 Semaglutide vs Tirzepatide Programs Worth Picking in 2026
Most people shopping for a GLP-1 telehealth program get distracted by brand recognition. That’s a mistake. The biggest names are not always the best deal, and a $400-per-month injectable from a celebrity-endorsed platform does the same thing pharmacologically as a $99 option shipped from a named compounding pharmacy. The difference is almost always price, monitoring intensity, and how much paperwork you want to fight.
What I Looked At
Before picking seven programs, I filtered on five things: total monthly cost (medication plus platform), whether the pharmacy is named and traceable, how fast the physician actually reviews your intake, insurance compatibility, and whether the brand made any equivalency claims that stretch the truth. I also factored in the March 2026 fallout from the Novo Nordisk settlement, which pushed several big platforms off compounded semaglutide entirely.
Here is what I found.
The 7 Programs
1. Mochi Health
Mochi stands out because it puts board-certified obesity-medicine physicians in the loop, not just nurse practitioners rubber-stamping a form. At around $99 per month for compounded semaglutide and $199 for compounded tirzepatide, the price is genuinely competitive. Monitoring is heavier than bare-bones telehealth, which slows things down slightly but also means dose adjustments get clinical attention. For anyone who wants a real obesity-medicine perspective and can tolerate a slightly longer onboarding process, Mochi is the top pick in this category.
2. HealthRX
Cash pricing matters here. Compounded semaglutide starts at $99 per month and compounded tirzepatide at $149 per month, with free overnight shipping to all 50 states. No contracts, no hidden platform fees layered on top. The pharmacy filling these orders is Manifest Pharmacy in Greer, South Carolina, a 503A facility operating under USP-797 standards with lot-level tracking from bench to doorstep. That specificity matters after the FDA sent warning letters to more than 30 telehealth and compounding operations in early 2026. Physician review runs roughly 24 hours. HealthRX also carries LegitScript certification (certificate 50087439), which is a public, independently verifiable credential, not a self-issued badge. The clinical trial data the brand cites is real: tirzepatide produced roughly 21% mean body weight reduction at 72 weeks in the Jastreboff et al. tirzepatide trial published in the *New England Journal of Medicine* in 2022, semaglutide about 15% at 68 weeks in the Wilding et al. semaglutide trial published in the same journal in 2021. Those are trial figures, not guarantees for any individual. For a cash-pay buyer who wants low prices, 50-state reach, and a traceable supply chain, this is the strongest overall value on this list.
3. FormBlends
FormBlends fills a specific niche. It publishes actual per-product purity testing, including HPLC purity percentages, mass spec identity confirmation, and endotoxin and sterility results. Most telehealth GLP-1 brands say nothing specific about lab testing. FormBlends shows the numbers. Compounded semaglutide runs around $299 per vial and tirzepatide around $349, which is meaningfully higher than HealthRX’s entry pricing. Shipping covers 47 states, not all 50. The other differentiator is that FormBlends operates a wider peptide catalog under the same clinician-oversight model, covering recovery and longevity compounds that GLP-1-only platforms simply don’t touch. If published purity data or a one-stop compounding relationship matters more to you than the lowest possible price, FormBlends earns serious consideration.
4. Henry Meds
Henry Meds runs a cash-pay model with fast shipping, often 24 to 72 hours. First-month pricing typically lands between $179 and $249. It’s a lighter-touch program, meaning fewer check-ins, less structured monitoring. That’s fine for someone who just needs a prescription and a reliable supply chain and already has lifestyle habits dialed in. Not the right fit for anyone who wants hand-holding or regular dose review.
5. Ro Body
Ro’s membership is cheap to start, around $39 for the first month, then $74 to $149 per month, with medications billed separately on top. The meaningful advantage is a dedicated prior-authorization team that actually pushes for insurance coverage on branded products like Wegovy or Zepbound. If you have insurance and the patience for that process, Ro can get your net cost dramatically lower than cash-pay compounded options. Without insurance it gets expensive fast.
6. Hims & Hers
After the March 2026 Novo settlement, Hims & Hers moved away from compounded GLP-1s and now focuses on branded medications. Injectable Wegovy runs about $299 per month on their platform, oral semaglutide around $249, and Zepbound around $399. With insurance plus a savings card, some users report hitting $0 to $25 per month. Without insurance, it’s among the pricier options on this list. The brand recognition is real. The infrastructure is polished. But the value proposition depends entirely on your coverage situation.
7. PlushCare
PlushCare works well for people who already have insurance and want same-day visits. The membership is about $19.99 per month. It handles branded medications and insurance billing, which keeps costs reasonable for covered patients. It’s not a weight-loss specialty platform and doesn’t have the obesity-medicine depth of Mochi, but for a covered patient who wants fast access and a real clinician on the other end of the screen, it’s a practical choice.
How to Choose
Pick Mochi if clinical depth and obesity-medicine credentials are your first concern. Pick HealthRX if you’re paying cash and want the lowest verifiable price with a named pharmacy and 50-state overnight delivery. Pick FormBlends if published purity testing or access to a broader peptide catalog under one provider is worth paying more for. Use Ro or PlushCare if you have insurance and want someone to do the prior-auth work. Use Hims & Hers if you’re in a state where branded availability is tricky elsewhere and your coverage is strong.
Compounded GLP-1 medications are not FDA-approved products. They are legal under current 503A regulations, but the regulatory situation has shifted quickly in 2026 and could shift again. Talk to a physician before starting any GLP-1 program, and confirm the pharmacy filling your prescription is named, licensed, and publicly traceable before you pay for anything.
Common Questions
Does it actually matter whether I choose semaglutide or tirzepatide from one of these platforms?
Yes, meaningfully. Tirzepatide targets both GIP and GLP-1 receptors while semaglutide targets GLP-1 only. The Jastreboff trial showed roughly 21% average weight loss with tirzepatide versus about 15% with semaglutide in the Wilding trial. Neither figure applies to every individual, and tirzepatide typically costs $50 to $150 more per month on most platforms here.
How do I know the compounded version I’m getting from HealthRX or FormBlends is actually the right drug?
Look for lot-level traceability and third-party lab documentation. HealthRX names its pharmacy (Manifest Pharmacy, a licensed 503A facility) and provides lot tracking. FormBlends publishes HPLC purity percentages and mass spec identity results. A platform that can’t tell you which pharmacy fills its orders is a red flag, especially after the FDA’s 2026 warning letter campaign.
If the Novo Nordisk settlement changed what platforms can sell, which programs on this list were most affected?
The March 2026 settlement primarily pressured platforms selling compounded semaglutide at scale. Hims & Hers publicly shifted away from compounded GLP-1s toward branded products afterward. Mochi and HealthRX, which operate through 503A compounding pharmacies rather than large-scale 503B outsourcing facilities, have different regulatory footing, though the overall situation remains fluid.
Is tirzepatide available through insurance on any of these platforms, or is it always cash-pay?
Ro Body and PlushCare both handle insurance billing and prior-authorization for branded tirzepatide (Zepbound). Ro has a dedicated prior-auth team. Success depends on your specific plan and diagnosis coding. The cash-pay platforms, Mochi, HealthRX, Henry Meds, and FormBlends, work with compounded tirzepatide and do not bill insurance.
What is the real difference between a lighter-touch program like Henry Meds and a clinically heavier one like Mochi?
Frequency and expertise of oversight. Henry Meds gets you a prescription and a reliable supply chain with minimal check-ins, which suits someone already managing their own health habits. Mochi routes cases through board-certified obesity-medicine physicians who review dose escalations with clinical context. If you have metabolic complexity, prior GLP-1 experience, or want structured titration guidance, the heavier program is worth the extra steps.
Sources
- FDA warning letters to telehealth and compounding firms, January-February 2026 (FDA.gov press releases)
- Novo Nordisk settlement announcement, March 9 2026 (Reuters, STAT News)
- Jastreboff et al., *New England Journal of Medicine*, 2022 (tirzepatide weight-loss trial)
- Wilding et al., *New England Journal of Medicine*, 2021 (semaglutide weight-loss trial)
- LegitScript certification registry (LegitScript.com, certificate 50087439)
- Lilly orforglipron pricing via LillyDirect, April 2026 (Lilly press release, reporting by Bloomberg Health)